The injectable drug delivery startup that raised $250M, won deals with AstraZeneca and Hikma, and collapsed after its CEO was charged with securities fraud.
Evaluating only Unilife Corporation’s profile at its peak — without knowing the outcome — the model ranked Fraud as the #1 likely cause. That’s exactly how it died.
Unilife built retractable syringe and injectable drug delivery systems, winning partnerships with AstraZeneca and Hikma. CEO Alan Shortall was charged by the SEC in 2017 with securities fraud for misrepresenting revenue timing and fabricating customer contract milestones to maintain stock price. Filed Chapter 11 May 2017.
Lesson
“Milestone reporting to public market investors in medical devices is subject to strict disclosure rules. Accelerating revenue recognition on long-cycle pharma contracts is securities fraud, regardless of whether the product works.”